Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Angel PRP gel is an autologous platelet-rich plasma (PRP)-based biotherapy developed by Biotherapy Services Ltd. for the treatment of complex and chronic wounds, such as diabetic foot ulcers. The product is prepared using the Angel™ PRP system, which centrifuges and fractionates a patient's own whole blood to produce concentrated autologous platelet-rich plasma (cPRP). This cPRP is then formulated into a gel for topical application. The therapeutic effect is driven by the release of high concentrations of growth factors and cytokines from the platelets, which stimulate the wound healing cascade, promote tissue regeneration, and accelerate repair in delayed-healing environments. It is currently being evaluated in the Project RAPID (Restorative Autologous Platelet Biotherapies for Injuries & Delayed Wound Healing) clinical trial.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Angel PRP gel.